FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 386 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma April 17, 2018 Blood Test for Early Detection of Cancer: Final Study Results Support... June 25, 2021 Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal... September 17, 2021 Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... December 20, 2023 Load more HOT NEWS Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling... Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates...
